RT Journal Article
SR Electronic
T1 Rapid Infusion of Ibandronate in Lung Cancer Patients with Bone Metastases
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3133
OP 3136
VO 26
IS 4B
A1 KIAGIA, MARIA
A1 KARAPANAGIOTOU, ELENI
A1 CHARPIDOU, ADRIANI
A1 DILANA, KALLIOPI
A1 DIONELLIS, GEORGIOS
A1 DANNOS, IOANNIS
A1 GEORGIOU, EVANGELLOS
A1 SYRIGOS, KONSTANTINOS N.
YR 2006
UL http://ar.iiarjournals.org/content/26/4B/3133.abstract
AB Background: The high prevalence of bone metastases in stage IV non-small cell lung cancer (NSCLC) patients contributes substantially to the burden of the disease by resulting in significant skeletal morbidity. Ibandronate is a new generation of bisphosphonates (BPs) with demonstrated clinical benefit in breast and prostate cancer patients with bone metastases. Patients and Methods: In 32 patients with newly diagnosed NSCLC and bone metastases, 4 mg of ibandronate were administered, as a rapid 20-minute intravenous infusion every 3-4 weeks. Results: A total of 189 infusions were administered over a 24-month period, during which a statistically significant decrease in calcium serum levels (p=0.03) was observed. The serum levels of alkaline phosphatase (ALP) were also decreased, but not significantly. With regard to clinical efficacy, 24 of our patients stabilized or reduced their need for analgesic treatment. The reduced time of infusion (20 min vs. 2 h) did not correlate with any side-effects, including vital sign deterioration and renal dysfunction. Conclusion: The rapid infusion of ibandronate in lung cancer patients with bone metastases is a safe and convenient procedure that may be administered in a day-clinic setting. Copyright© 2006 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved